SESSION VI: MULTIPLE MYELOMA

Session Chairs: Krina K. Patel, MD, MSc and Thomas G. Martin, MD

Controversies in Amyloidosis – Novel Therapies | Suzanne Lentzsch, MD, PhD | Columbia University, New York, New York, USA

Update on CAR T Therapy in MM | Noopur Raje, MD | Massachusetts General Hospital, Boston, Massachusetts, USA

Future on Bispecifics and ADCs | Krina K. Patel, MD, MSc | MD Anderson Cancer Center, Houston, Texas, USA

Debate: Frontline + Maintenance – Until PD | Thomas G. Martin, MD | University of California, San Francisco, California, USA

Debate: Frontline + Maintenance – Guided by MRD (Fixed Duration) | Robert Orlowski, MD, PhD | MD Anderson Cancer Center, Houston, Texas, USA

Resistance to Immunotherapy | Paola Neri, MD, PhD | University of Calgary, Calgary, Canada

Novel Technologies | Angela Dispenzieri, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Is It Time to Say “CURE” in Multiple Myeloma? | Sundar Jagannath, MD | Mount Sinai Hospital, New York, New York, USA

Oral Abstract | MM-906: First-in-Human Study of JNJ-79635322 (JNJ-5322), a Novel Next-Generation Trispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Phase 1 Results | Hans Lee, MD | Sarah Cannon Research Institute Nashville, Tennessee, USA